Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ADC Therapeutics SA

ADCT ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NYSE · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.27

▲ +3.25%

Market Cap $162.14M · Vol 331.16K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$162.14M

Micro Cap

Div Yield

N/A

EPS Growth

+29.24%

YoY

RSI (14)

65.71

Momentum

Beta

1.88

vs Market

52W High

$4.97

74.45% below

52W Low

$0.78

62.90% above

Volume

331.16K

Avg 368.67K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

85.58%

Public shares

Shariah Compliance8 STANDARDS

✗ ADC Therapeutics SA (ADCT) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADCT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.25%

-6.62%

+1.60%

-65.40%

YTD

-64.02%

-71.33%

+51.19%

-94.67%

Financials & Valuation

TTM · Annual

Total Revenue	$81.36M
Net Income	$-142,623,000.00
Revenue Growth (YoY)	+2.17%
Gross Margin	92.87%
Operating Margin	-133.21%
Net Profit Margin	-175.31%
ROE	N/A
ROA · ROIC	-43.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.51
P/B	N/A
P/FCF	N/A
EPS Growth	+29.24%
Outstanding Shares	127.67M

Technical Indicators

50-Day SMA	$1.14
200-Day SMA	$2.67
RSI (14)	65.71
Beta	1.88
52-Week High	$4.97
52-Week Low	$0.78

Volume Today	331.16K
Avg Daily Volume (30D)	368.67K
Relative Volume	0.90x
Volatility (10D)	86.86
Volatility (30D)	81.30
Free Float	85.58%

Analyst Consensus

BUY

Current Price $1.27

Mean Target $2.63

52W Low$0.78 52W High$4.97

Current

Target

$0.78 $4.97

Current Analyst target

+106.69% upside potential · 5 analysts

Identifiers

ExchangeNYSE

FIGIBBG00Q6Q3RN0

ISINCH0499880968

CountrySwitzerland

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.92% ARGX.BR argenx SE +2.76% ARGX argenx SE +1.93% 2269.HK WuXi Biologics (Cayman) Inc. +4.51% GMAB Genmab A/S -1.77%

Company Profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.